Teva CEO Calls 'Trough' Revenues Consequence of Patent Expirations

The video discusses the company's ongoing efforts to cut costs by closing manufacturing facilities and reducing debt. It highlights the financial targets set to stabilize the company, including reducing net debt and maintaining cash earnings. The CEO provides insights into market guidance, emphasizing realistic and conservative projections. The stabilization of generic drug pricing is addressed, along with the company's strategic focus on becoming a leading generic and biopharmaceutical company.

What factors contributed to the company's revenue and operating profit expectations for 2019?

What is the company's strategy regarding generic drug pricing?

How does the company plan to balance innovation and affordability in its drug offerings?